# Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients

> **NCT00851318** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 285 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Certolizumab pegol
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT00851318
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 285 (ACTUAL)
- **Last updated:** 2014-11-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00851318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00851318, "Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00851318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*